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Abstract We analyzed morphological and immunohisto-
chemical features in 174 aggressive B-cell lymphomas of
nodal and extranodal origin. Morphological features included
presence or absence of a follicular component and cytologic
criteria according to the Kiel classification, whereas immuno-
histochemical studies included expression of CD10, BCL-2,
BCL-6, IRF4/MUM1, HLA-DR, p53, Ki-67 and the assess-
ment of plasmacytoid differentiation. Patients were treated
with a CHOP-like regimen. While the presence or absence of
either CD10, BCL-6 and IRF4/MUM1 reactivity or plasma-
cytoid differentiation did not identify particular cytomorpho-
logic or site-specific subtypes, we found that expression of
CD10 and BCL-6, and a low reactivity for IRF4/MUM1 were
favourable prognostic indicators. In contrast, BCL-2 expres-
sion and presence of a monotypic cytoplasmic immunoglob-
ulin expression was associated with an unfavourable
prognosis in univariate analyses. Meta-analysis of these data
resulted in the development of a cumulative immunohisto-
chemical outcome predictor score (CIOPS) enabling the
recognition of four distinct prognostic groups. Multivariate
analysis proved this score to be independent of the interna-
tional prognostic index. Such a cumulative immunohisto-
chemical scoring approach might provide a valuable
alternative in the recognition of defined risk types of
aggressive B-cell lymphomas.
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Diffuse large B-cell lymphomas (DLBCL) comprise a hetero-
geneous category of malignant Non-Hodgkin lymphomas
(NHL)withrespecttomorphology,immunophenotype,genetic
features, and clinical course [1]. The striking differences
regarding outcome, especially, have prompted the assumption
that this lymphoma type includes different disease entities and
that their delineation might allow the assignment of tailored
treatment approaches to defined risk profiles. These attempts,
in the past, aimed at the assessment of morphological criteria,
such as the separation of immunoblastic and centroblastic
types [2], the evaluation of genetic aberrations [3]a n dc e r t a i n
biological features, such as the proliferation index [4–6], or
the expression of relevant proteins like BCL-2 [7–11].
Gene expression profiling using cDNA and oligonucleo-
tide microarrays proved to be a powerful tool both in the
delineation of two main differentiation phenotypes in
DLBCL, namely a germinal center (GC) B-cell like and an
activated B-cell like (ABC) DLBCL type, as well as in the
recognition of prognostically relevant gene expression pro-
files [12–14]. The striking clinical impact of distinguishing
GC- and non-GC types of DLBCL, demonstrated in the
CHOP-, but more recently also in the R-CHOP treatment era
[15], led to the search of individual genes or smaller numbers
of genes the expression of which might facilitate their
recognition in order to make this approach amenable to
routine diagnostic practice [16–19]. This approach also
includes the widely used Hans-algorithm [17]. However, a
number of studies provided highly variable and conflicting
data questioning their suitability to define robust clinical risk
groups [16, 17, 20–29]. By investigating well known
markers which correlate with a germinal center or post-
germinal center differentiation (CD10, BCL-6, IRF4/
MUM1) as well as other markers of potential prognostic
importance [17, 30, 31] we constructed, as a new approach, a
cumulative immunohistochemical outcome predictor score
resulting in the delineation of four distinct prognostic groups.
Material and methods
Specimen selection
Inclusion of samples required the availability of diagnostic
material (paraffin blocks) and that the patient had not been
treated before biopsy. Therefore, samples from patients with
known preceding low-grade lymphoma were excluded. Mate-
rial from 166 DLBCL patients fulfilled these criteria. Of these,
10 DLBCL had an additional follicular lymphoma grade 3B
(DLBCL + FL3B) component, and 13 tumors harbored an
additionalFL3A area. Because of their striking morphological,
immunophenotypic and genetic similarities with diffuse large
B cell lymphomas [32], we also included 8 purely follicular
lymphomas grade 3B (FL3B). Thus, altogether, specimens
from 174 patients with aggressive large B-cell tumors
diagnosed between 1990 and 2003 were enrolled in this
study. Clinical data were available from referring clinicians in
all patients (Table 1). All patients, with a single exception,
were treated with a CHOP or CHOP-like chemotherapy
regimen. The study was approved by the Local Ethics
Committee of the University of Würzburg, Germany.
Nodal and extranodal origin of tumors
The large majority of lymphomas arose in the lymph nodes,
while other lymphatic organs primarily infiltrated were the
spleen in six cases and the pharyngeal tonsil in another six
cases. 28 tumors presented with primary extranodal origin,
the majority of them (n=17) in the stomach but also in the
thyroid gland (6 cases), the small and large intestine
(3 cases), the breast and sinus maxillaries (1 case each).
Table 1 Major clinical features of the patient cohort
Clinical parameter No. of patients
Gender
Male 92
Female 81
N/A 1
Age (y)
Median (range) 63 (8–94)
No more than 60 73
More than 60 100
N/A 1
Ann Arbor stage
I2 6
II 29
III 35
IV 31
N/A 53
LDH
Normal 42
High 74
N/A 58
IPI group
Low (0–1) 38
Intermediate (2–3) 37
High (4–5) 13
Not classified 86
B Symptoms
Yes 49
No 70
N/A 55
Median follow-up (range) 33 months (1–163)
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All cases were reviewed on whole tissue sections stained
for Hematoxylin and Eosin, Giemsa, Periodic acid-Schiff
(PAS) and Gomori’s silver impregnation. Diagnoses were
made according to the criteria of the WHO classification of
2008 and, in addition, variants were described according to
the criteria of the Kiel classification in diagnosing
centroblastic-monomorphic, centroblastic-multilobated and
centroblastic-polymorphic lymphomas [33]. In DLBCL
with an additional FL3 component, the presence of
follicular dendritic cell networks was confirmed by immu-
nostaining using appropriate antibodies (CD21, CD23), and
follicular structures had to be present in at least 25% of the
infiltrated areas.
Immunohistochemistry
For diagnostic purposes, immunostaining was performed on
paraffin sections using B-cell markers CD20 (Clone L26,
DAKO, Glostrup, Denmark, 1:1000) and CD23 (Clone
1B12, NOVOCASTRA, Newcastle upon Tyne, United
Kingdom, 1:80) and T-cell markers CD3 (NOVOCASTRA,
1:80) and CD5 (Clone 4C7, NOVOCASTRA, 1:40).
Proliferation indices (PI) were estimated in areas with the
highest reactivity and recorded in increments of 10% after
staining with the MIB1 antibody (MM1, NOVOCASTRA,
1:30) detecting the Ki67 antigen. The expression of CD10
was assessed using the antibody NCL-CD10 270 (NOVO-
CASTRA, 1:100). BCL-6 was detected using the PG-B6p
antibody (DAKO, 1:20) and IRF4/MUM1 staining in-
volved the MUM1p antibody (DAKO, 1:8000), also
evaluated in increments of 10%. HLA-DR expression was
analyzed using clone IQU9 (NOVOCASTRA, 1:80).
The expression of p53 was investigated on paraffin
sections using the DO-7 antibody (DAKO, 1:40). To score
a case as positive, strong nuclear expression in at least 20%
of cells was required. To assess plasmacytoid differentiation
(CIg+), intracytoplasmic immunoglobulin was detected
with antibodies to kappa and lambda light chains and in
some cases to IgM (all DAKO, 1:20000). An unequivocal
monotypic cytoplasmic reactivity was required to score a
case as CIg+. BCL-2 expression was evaluated on paraffin
sections using the antibody from DAKO (Clone 124,
1:400). A reactivity of >20% of cells was regarded as
positive. The presence of follicular dendritic cell (FDC)
meshworks was ascertained either by staining for CD23
(Clone 1B12, NOVOCASTRA, 1:80) or by using an
antibody to CD21 (Clone 1F8, DAKO, 1:200). All
immunohistochemical reactions on paraffin were performed
using the peroxidase anti-peroxidase (PAP) method after
antigen retrieval [34]. The quantitative assessment of
immunohistochemical staining evaluation was performed
according to the scoring guidelines recommended by de
Jong and co-workers [35].
Statistical analyses
Frequencies in different parameters were compared and
analysed using the chi-square test, t-test for independent
variables, or other appropriate tests, respectively, depending
on the nature of data. Overall survival (OS) was measured
from the date of diagnosis to death from any cause or to last
follow-up. OS distributions were calculated according to
the methods described by Kaplan and Meier. Time to event
distributions were compared using the log-rank test. A
multivariate analysis including the risk factors of the
international prognostic index (IPI) was carried out to
determine independent predictors of survival by using the
Cox proportional hazard model for survival analysis and
Pearson’s correlation. A p value of <0.05 was regarded as
statistically significant.
Results
Clinical data
Clinical data were available for all patients listed in Table 1.
Age distribution showed a peak in the 7th decade with a
slight male predominance. The patients presented with
advanced disease (Ann Arbor stages III and IV) in more
than half of the cases. The median follow up time was
33 months ranging from 1 month to 163 months.
Primary localization of lymphomas and morphology
132 lymphomas arose in lymph nodes, while in 12
additional cases the largest and/or only tumor mass was
found in the tonsil or spleen, respectively (6 cases each).
Two tumors involved the bone marrow exclusively, with
leukemic spread. 28 DLBCL presented with a primary
extranodal localization. The stomach was the most frequent
extranodal site involved (17 cases), while the other sites
were the thyroid gland (n=6), the small and large intestine
(n=3), the breast, and the maxillary sinus (n=1 each). 143
tumors were pure DLBCL, while 23 cases had a detectable
follicular component. Ten cases were classified as DLBCL
with a FL3B component, and 13 DLBCL showed an
additional FL3A component (most of them with a multi-
lobated cytology). Eight lymphomas were purely follicular
FL3B. All extranodal tumors were classified as DLBCL.
All lymphomas with a predominantly diffuse component
(i.e. DLBCL ± minor FL component) involving lymph
nodes, spleen or tonsils were subclassified according to the
Kiel classification as centroblastic-monomorphic and/or
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polymorphic (28 cases) and immunoblastic (24 cases)
lymphomas.
Immunophenotypes
Due to loss of material, complete immunophenotypes were
available in 145 cases. CD10 was expressed in 57/145
evaluable cases (39%). In contrast to this antigen, that was
usually either homogeneously present or absent on all
tumor cells, both BCL-6 and IRF4/MUM1 reactivities
varied considerably ranging from 0% to 100% of cells in
a given tumor. A high expression of BCL-6 in ≥70% of
nuclei, like in the reactive germinal center (GC) was
encountered in 73 (50%) lymphomas, while 43 tumors
(30%) showed an intermediate reactivity (20%–60%). No
or low levels of BCL-6 expression (<20%) were seen in 27
tumors. IRF4/MUM1 was positive in ≥50% of nuclei in 45
cases (31%). BCL-2 was expressed in 100 lymphomas
(69%). The Ki-67 antigen was expressed in ≥80% of nuclei
in 82 tumors (57%). A monotypic cytoplasmic immuno-
globulin expression could be detected in 62 of 145 (43%)
cases. P53 was overexpressed (≥20% positive tumour cells)
in 29 of 143 (20%) DLBCL. HLA-DR expression was
present in 121 of 124 cases (98%). Only 3 cases showed no
expression (<10% of cells).
Heterogeneity of immunophenotypes
In contrast with the rather ordered immunophenotypic profile
encountered in the various compartments of reactive lymphoid
tissues, the expression of immunophenotypic markers was
highly heterogeneous in the lymphoma cases. For example,
BCL-2 was expressed in 37/57 (65%) CD10 positive tumors,
in comparison with 63/88 (72%) CD10 negative cases; seven
CD10-positive tumors (12%) also expressed the post-germinal
marker IRF4/MUM1 in at least 50% of cells.
Overall, there was a strong positive correlation between
the expression of CD10 and BCL-6, while CD10 positivity
was negatively correlated with MUM1 reactivity. In highly
proliferative tumours (Ki-67 index≥80%), there were more
lymphomas with BCL-6 expression (44/54) and CD10
expression (34/54). In contrast, tumors with proliferation
indices <80% harbored fewer cases with a GC phenotype,
but were more often IRF4/MUM1 and BCL-2 positive.
There was a wide distribution of the different morpho-
logic subtypes within the GC-related and non-GC-related
lymphomas according to the Hans classifier [17]. 37/44
(84%) multilobated centroblastic lymphomas (CB) were
GCB DLBCL, as were all multilobated centroblastic
DLBCL with a FL3A component. Only 16/27 (59%) of
the centroblastic polymorphic DLBCL were of GCB type.
In contrast, 18/21 (86%) immunoblastic lymphomas (IB)
were non-GCB related. It is interesting to note that among
tumors other than multilobated centroblastic cases, purely
follicular FL3B tumors were more often of GCB type (6
GCB, 2 non-GCB), while DLBCL with a FL3B component
predominantly fell into the non-GCB group (3 GCB, 7 non-
GCB). Primarily extranodal lymphomas were GCB (n=13)
and non-GCB (n=14) types in equal distribution.
Correlations with survival
Within 145 lymphomas with a complete immunophenotype,
121 tumors with nodal, splenic or tonsillar involvement and
24primarilyextranodalDLBCLhadfollow-updataavailable.
Adverse clinical variables withregard tooverall survival (OS)
were elevated LDH levels (p<0.001), presence of B
symptoms (p=0.002), and age >60 years (p=0.04). The IPI
also was a powerful outcome predictor (p<0.001).
Neither the presence of a (partly) follicular growth
pattern (p=0.9), nor the primary site of involvement
(nodal/extranodal) predicted survival (p=0.7).
In univariate analysis, the following immunohistochem-
ical parameters predicted an unfavourable prognosis: BCL-
2 expression irrespective of staining intensity (p<0.001),
CD10 negativity (p<0.02), BCL-6 expression in <20% of
cells (p<0.001), IRF4/MUM1 reactivity in ≥50% of nuclei
(p<0.02), and monotypic cytoplasmic immunoglobulin
expression (CIg+) (p<0.03). In addition, in the present
series, stratification of the tumors into GC-related and non-
GC-related types according to the criteria described by
Hans et al. [17] was predictive of survival and showed a
GC differentiation to represent a favourable parameter
(p<0.01; Fig. 1). Univariate analyses of HLA-DR and
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Fig. 1 Stratification of the tumors according to the Hans algorithm
was predictive of survival and showed a GC differentiation to
represent a favourable parameter in the Kaplan-Meier model
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statistically significant correlations with survival.
Development of a cumulative immunohistochemical
outcome predictor score (CIOPS)
To test whether the patients could be more accurately
categorized into favourable and poor-risk groups we
devised a cumulative scoring system based on the sequen-
tial addition of negative prognostic indicators in a given
tumor (cumulative immunohistochemical outcome predic-
tor score: CIOPS). Each variable that emerged as prognos-
tically negative in univariate analysis (CD10 negativity,
BCL-6 expression in <20%, BCL-2 positivity, MUM1/
IRF4 expression in ≥50%, cytoplasmic immunoglobulin
expression) was scored as one negative factor, and the sum
of negative factors resulted in a risk score that ranged from
zero to five in each given case.
When the prognostic effect of the score was analyzed
in the 145 patients using the Kaplan-Meier model, a
dramatic difference in survival was recognized between
cases without risk factors (score: zero), cases with 1–2
adverse prognostic factors, cases with 3–4a d v e r s e
prognostic factors, and cases with a score of five
(p<0.0001; Fig. 2).
In the favourable prognostic group with 14 patients, all
patients except for one survived. Review of the medical
report indicated that this patient was an 80-year old woman
who, after diagnosis, refused further treatment. In contrast,
in the group with a CIOPS score of five 7 of 8 patients died
(the surviving patient was a 65 year old male with an initial
Ann Arbor stage 2 and an IPI of 2, follow up time
83 months). The survival curves of the remaining 123
patients with intermediate scores (1–4) were also different
with the possibility to distinguish a favorable intermediate
(scores 1–2) and a poor intermediate group (scores 3–4)
that show significant differences in survival (p=0.0398). In
multivariate analysis, the cumulative immunohistochemical
outcome predictor score proved to be independent of the
IPI index, including age, stage of disease, elevated serum
LDH, B-symptoms and extranodal manifestation.
Table 2 gives an overview of the distribution of the
immunophenotypes in the different CIOPS subgroups. As
can be seen from this table, the immunohistochemical
features dividing the tumors into CIOPS groups 2 and 3
were variable. Using the algorithm of Hans et al. [17]
CIOPS group 2 contained 61 GCB and 12 non-GCB cases,
and group 3 contained 40 non-GCB and 10 GCB cases. The
two most important features that discriminated between the
groups 1 and 2 were more frequent BCL-2 positivity or
CD10 negativity in group 2. Monotypic cytoplasmic
immunoglobulin expression or IRF4/MUM1 expression
was a classifying feature in group 3.
No morphological subtypes clustered within a distinct
CIOPS group. Those immunoblastic lymphomas, for whom
immunohistochemistry was available (n=10), were more or
less equally distributed among different CIOPS groups
(CIOPS 2: 2 cases; CIOPS 3: 3 cases; CIOPS 4: 2 cases;
CIOPS 5: 1 case), although none were found in low CIOPS
group.
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Fig. 2 Overall survival of all 145 patients stratified according to the
CIOPS score with a dramatic difference in survival between cases
without risk factors (score null), cases with 1–2 adverse prognostic
factors, cases with 3–4 adverse prognostic factors, and cases with a
score of five
Table 2 Overview of the distribution of the immunophenotypes in the different CIOPS subgroups
CIOPS
group
CIOPS-
Score
number
of cases
nonGCB/
GCB
CD10 positive/
negative
BCL-6 positive/
negative
cIg positive/
negative
BCL-2 positive/
negative
MUM1p
positive/
negative
1 0 14 0/14 14/0 (100/0%) 14/0 (100/0%) 0/14 (0/100%) 0/14 (0/100%) 0/14 (0/100%)
2 1 42 5/37 28/14 (67/33%) 40/0 4/38 (10/90%) 24/18 (57/43%) 2/40 (5/95%)
2 31 7/24 11/20 (55/45%) 29/2 (94/6%) 13/18 (42/48%) 24/7 (77/23%) 3/28 (10/90%)
3 3 24 14/10 4/20 (20/80%) 18/6 (75/25%) 14/10 (58/42%) 20/4 (83/17%) 12/12 (50/50%)
4 26 26/0 0/26 (0/100%) 15/11 (58/42%) 23/3 (88/12%) 24/2 (92/8%) 20/6 (77/23%)
4 5 8 8/0 0/8 (0/100%) 0/8 (0/100%) 8/0 (100/0%) 8/0 (100/0%) 8/0 (100/0%)
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Diffuse large B-cell lymphomas comprise a heteroge-
neous group of lymphoid tumors with varying morphol-
ogy, immunophenotypes, genetic characteristics, and
clinical course. Previous studies have aimed at the more
accurate definition of their risk profiles using different
criteria such as morphology [2, 36, 37], protein expres-
sion patterns targeting several proliferation or apoptosis
related antigens [4, 5, 7–11, 38, 39]o rt h e i rg e n e t i c
constitution [3, 40, 41].
Because of the conflicting data resulting from earlier
studies on the value of immunohistochemical marker
expression in DLBCL [17, 20, 22, 25, 42, 43], we applied
a novel, slightly different approach and constructed a
cumulative immunohistochemical outcome predictor score
(CIOPS) to divide DLBCL patients into various risk
groups. Following the notion that—in contrast to normal
B-cell differentiation - dual expression of both GC-related
and GC-unrelated markers [e.g. BCL-6 and IRF4/MUM1
[44]] can be frequently observed in the same tumor, the
immunohistochemical assignment to the GCB- or non-GCB
group appears problematic.
In the present study, the combined analysis of antigens
having been related to either a germinal center differen-
tiation of normal reactive and tumor cells, such as CD10
and BCL-6, or pointing to a postfollicular differentiation
step (IRF4/MUM1, plasmacytoid differentiation) has
clearly confirmed the heterogeneity of antigen expression
patterns in DLBCL as compared with compartments of
the reactive lymphoid tissues [44–47]. Nevertheless,
statistical analysis revealed a strong positive correlation
of CD10 and BCL-6 expression on one hand, and of IRF4/
MUM1 expression and plasmacytoid differentiation on the
other hand. Moreover, in univariate analysis, expression of
both CD10 and BCL-6 identified prognostically relevant
favourable subgroups, while IRF4/MUM1 reactivity in
50% or more of tumor cells characterized tumors with an
inferior prognosis. In our study, two additional features
were of value for identifying risk groups, namely the
expression of BCL-2 and the assessment of plasmacytoid
differentiation of the tumor cells. While the negative
prognostic impact of BCL-2 expression in DLBCL is well
established [7–11], few studies have addressed the
possible importance of plasmacytoid differentiation in
DLBCL. Simonitsch-Klupp and colleagues [48]d e m o n -
strated that plasmablastic/plasmacytoid differentiation
represents a significant risk factor in DLBCL. Immuno-
blastic morphology, which frequently goes along with
plasmacytoid differentiation, has been repeatedly identi-
fied as a risk factor in DLBCL [2, 37]. The prognostic
importance of plasmacytoid differentiation using the
analysis of kappa and lambda light chain expression in
the cytoplasm of the tumor cells, however, has not been
evaluated so far.
Given the promiscuous expression of GC- and non-GC
related proteins in a subset of DLBCL which makes the
strict categorization into GCB and non-GCB DLBCL
groups difficult at the immunohistochemical level, we
investigated the possible clinical impact of a model that
sequentially adds risk markers rather than basing risk
assessments on decision trees. Specifically, by assigning
equal weights to each of the immunophenotypic features
identified in univariate analysis, we developed a cumulative
immunohistochemical outcome predictor score (CIOPS).
To each case, an individual risk score from zero to five is
attributed which is based on prognostically negative factors
including the absence of CD10 expression, BCL-6 reactiv-
ity in <20% of cells, IRF4/MUM1 positivity in ≥50% of
nuclei, BCL-2 expression, and plasmacytoid differentiation
of the tumor cells. Plotting the survival of the different
patient cohorts according to the CIOPS group revealed four
highly distinct survival curves with a low-risk group
consisting of patients characterized by a score of zero,
patients with a high-risk score of 5 with a dismal course and
two intermediate groups with CIOPS scores 1 and 2 and 3
and 4, respectively. Multivariate analysis comparing the
CIOPS score to the IPI stressed its independent prognostic
value in clinical risk assessment. Besides the delineation of
four distinct prognostic subgroups, the CIOPS score also
identifies two patient cohorts at the extremes of the
spectrum with striking differences in the mortality rates
(7% vs. 100%) which might be a valuable feature towards
future risk adapted therapeutic strategies. Clearly, any
prognostic significance of the CIOPS score has to be
studied in the context of an independent study cohort with
an increased number of patients suffering from DLBCL.
One major caveat to the interpretation of these data is
that the investigated patient cohort stems from the pre-
Rituximab era. However, a recent major gene expression
profiling study suggests that many molecular features with
prognostic significance in the CHOP treatment era are
retained in the CHOP-R treatment era [15]. Therefore,
studies that are already under way will have to determine
whether our cumulative immunohistochemical model might
also be of predictive value in patient cohorts treated with
current protocols.
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